Special Materials with Out-of-Pocket Co-payments: Two Categories Exceeding 70%, and the Curve that Dropped from 70.5% to 9.2%

In 2024, the overall reporting rate for National Health Insurance (NHI) special materials with out-of-pocket co-payments was 0.0569%. Among ten major categories, four are rising annually, with coronary drug-eluting stents (73.1%) and intramedullary nail sets (79.3%) both exceeding 70%. Following the inclusion of cerebrospinal fluid shunt systems in full coverage in 2022, their rate dropped from 70.5% to 9.2%.

In 2024, the overall reporting rate for special materials with out-of-pocket co-payments under National Health Insurance (NHI) was 0.0569%.1

In that same year, coronary drug-eluting stents accounted for 73.1%, while intramedullary nail sets with special functions and materials accounted for 79.3%.1

While the overall figure is less than one-tenth of one percent, individual items exceed 70%. This article addresses this discrepancy.

Zero Point Zero Five Six Nine Percent

Let's start with the macro numbers. The calculation for the reporting rate of special materials with out-of-pocket co-payments is: the number of reports for such materials divided by the total number of reports for all special materials.1

The rates were 0.0523% in 2022, 0.0551% in 2023, and 0.0569% in 2024—a slight upward trend over three years, averaging approximately 0.0547%.1

This number is so small it is easily overlooked. However, the denominator includes all special materials, including those under full coverage; to see the real situation, one must look at specific categories.

Two Categories Exceeding 70%

The NHI splits special materials with out-of-pocket co-payments into ten major categories, each using a different calculation: the numerator is the volume of co-payment reports for the same use, and the denominator is the sum of co-payment reports plus full-coverage reports for that same use.1

In 2024, the highest proportion was intramedullary nail sets at 79.3%, followed by coronary drug-eluting stents at 73.1%.1

The remaining categories in descending order are: special function intraocular lenses (49.2%), special function pacemakers (49.1%), special function catheters for treating complex arrhythmia (46.9%), drug-eluting devices for treating superficial femoral artery stenosis (46.2%), special material biological tissue heart valves (43.2%), special material artificial hip joints (31.3%), cerebrospinal fluid shunt systems (9.2%), and prosthetics (4.1%).1

2024 Reporting Rate of 10 Major Categories of Special Materials with Co-payments (%)
Intramedullary nail sets
79.3 Last 3 years: 76.5→77.9→79.3
Coronary drug-eluting stents
73.1 70.2→72.3→73.1
Intraocular lenses
49.2 44.5→47.2→49.2
Pacemakers
49.1 48.2→49.3→49.1
Arrhythmia catheters
46.9 53.0→59.0→46.9

Source: NHI Committee "2024 National Health Insurance Supervisory Indicator Monitoring Results Report," Indicator 4.3

Analysis by the National Health Insurance Committee (NHIC) indicates that the reporting rates for coronary drug-eluting stents and intramedullary nail sets have exceeded 70%, meaning they are "approaching routine use." The NHIC has repeatedly requested the National Health Insurance Administration (NHIA) to evaluate including them in full coverage.1

Four Rising, One Falling

Over the last three years, four major categories have seen their proportions rise annually: intraocular lenses, coronary drug-eluting stents, drug-eluting devices for treating superficial femoral artery stenosis, and intramedullary nail sets.1

One category has seen a significant decline: cerebrospinal fluid shunt systems dropped from 70.5% in 2022 to 12.0% in 2023, and 9.2% in 2024.1

The remaining five categories are largely stable or fluctuating; for example, arrhythmia catheters rose from 53.0% to 59.0% before dropping back to 46.9%.1

Co-payment Proportion of Cerebrospinal Fluid Shunt Systems (%)
Co-payment Proportion of Cerebrospinal Fluid Shunt Systems (%)129.22023202470.5
Co-payment Proportion of Cerebrospinal Fluid Shunt Systems (%)
202270.5Included in coverage starting Nov 1 of that year
202312
20249.2

Source: NHIC "2024 National Health Insurance Supervisory Indicator Monitoring Results Report," Indicator 4.3

That One Time Full Coverage Was Implemented

The turning point for cerebrospinal fluid shunt systems has a specific date. Starting November 1, 2022, the NHIA included two high-market-share sub-functional categories of these materials into full NHI coverage.1

NHIC analysis shows that after being included in full coverage, the reporting rate showed a downward trend year by year. From 70.5% to 9.2%, a drop of over 60 percentage points.1

The significance of this case is not to prove that "full coverage causes a drop," but to demonstrate how the system works: when the usage rate of a certain category of special materials with co-payments remains high for a long time, the NHIC will request a review. After evaluation by the NHIA, it can be moved into full coverage, and that "co-payment" slot disappears.

The NHIC Threshold

The NHIC has established a principle: if the usage proportion of special materials with co-payments increases annually and exceeds 50%, an evaluation should be initiated—balancing citizens' medical needs with NHI financial stability—to include highly demanded, urgent, or essential materials in full coverage.1

Looking back at 2024 through this lens, only intramedullary nail sets (79.3%) and coronary drug-eluting stents (73.1%) crossed the 50% threshold; intraocular lenses (49.2%) and special function pacemakers (49.1%) are close to the threshold.1

The progress of the NHIA's handling varies. Coronary drug-eluting stents are moving toward "bundled payment for clinical items," prioritizing full coverage for patients with ST-segment elevation myocardial infarction (STEMI). For intramedullary nail sets, the NHIA has requested a Health Technology Assessment (HTA) from the Taiwan Food and Drug Administration's Center for Drug Evaluation. The commission is expected in March 2025, with the report completed by July. The estimated cost of transitioning to full coverage is approximately NT$450 million (calculated based on 2023 reporting volumes).1

How to Read This Table

This table is most easily misread in two ways.

The first is to look only at the overall 0.0569% and conclude that "the co-payment issue is not a big deal." This number is correct, but it averages out the massive differences between the ten major categories.

The second is to look only at 79.3% and conclude that "NHI is making citizens pay for everything themselves." This number is also correct, but it only represents the intramedullary nail category, and this ratio is determined by its definition: the denominator only counts co-payment and full-coverage reports for the same use. A high proportion means the volume of full-coverage items is relatively low.1

A more accurate reading is: a co-payment is an "option" slot. For most special materials, this slot is very small; for a few high-priced materials, this slot is very large. The system design ensures that this slot moves according to coverage policies—the cerebrospinal fluid shunt system is an example of a slot that was moved.

The next time the NHIC publishes this table, two things are worth watching: whether intramedullary nail sets and coronary drug-eluting stents will follow the path of cerebrospinal fluid shunt systems, and whether those four rising categories will push the overall proportion above 0.0569%.

Further Reading:

References

  1. 2024 National Health Insurance Supervisory Indicator Monitoring Results Report (National Health Insurance Committee, Ministry of Health and Welfare, November 2025) — Indicator 4.3 specifies the overall reporting rates for special materials with co-payments from 2022–2024 (0.0523%, 0.0551%, 0.0569%) and the proportions of the 10 major categories (intramedullary nail sets 76.5%, 77.9%, 79.3%; coronary drug-eluting stents 70.2%, 72.3%, 73.1%; intraocular lenses 44.5%, 47.2%, 49.2%, etc.), as well as the drop in cerebrospinal fluid shunt systems from 70.5% to 9.2% after inclusion in full coverage on November 1, 2022; the NHIC 50% threshold principle; and the NT$450 million financial estimate and HTA timeline for intramedullary nail sets.↩234567891011121314151617
About this article This article was collaboratively written with AI assistance and community review.
Tags
Out-of-pocket co-payment medical devices National Health Insurance medical expenses benefits health policy
Share

Further Reading

You might also like

Economy Evolving · Awaiting fact-check

NHI Expenditure Structure: Drug Costs at 27.71%, and Special Projects Growing from 36 to 61 Items

In 2024, the NHI's overall drug cost ratio reached 27.71%, a slight increase from 27.32% in 2022; excluding new drug costs, the ratio also rose from 24.2% to 26.0%, with medical centers exceeding 36%. Meanwhile, NHI special projects grew from 36 items in 2020 to 61 in 2024, a 69.4% increase, with hospital-sector projects growing 92.3%. Hospital overall execution rates remained below 80%, while dental outpatient rates rose to 91.11%. This article uses NHIA monitoring indicators to examine these two expenditure trends and reasons for low execution rates in some new projects.

閱讀全文
Lifestyle Evolving · Awaiting fact-check

Tiered Medical Care: Primary Care Accounts for 90%, Yet Medical Centers Still Treat Minor Illnesses

In 2024, primary care outpatient visits reached 92.01% of the total, while hospital shares fell to 35.91%. However, primary care rates at medical centers are rising; the NHIA is deploying strategic alliances and referral point adjustments to address this.

閱讀全文
Economy Evolving · Awaiting fact-check

NHI Finances: NT$23.4 Billion Surplus, 2.4 Months of Safety Reserves, and Consecutive NT$20 Billion Subsidies

The actual NHI surplus for 2024 was NT$23.402 billion, exceeding the estimated deficit of -NT$1.787 billion by NT$25.189 billion; safety reserves reached NT$162.2 billion (2.40 months), within the legal 1–3 month range. While NHI spending is 3.37% of GDP, Taiwan's 7.3% share of current healthcare expenditure remains lower than Japan, South Korea, and Germany. Since 2023, the government has provided multiple subsidies, including NT$20 billion each for 2024 and 2025. This article analyzes changes in surplus, safety reserves, subsidies, and copayment ratios using NHI Board financial indicators.

閱讀全文
Lifestyle Evolving · Awaiting fact-check

Surgical Site Infections: 1.21% Overall, with Half of Hospitals Reporting Zero Infections

The 2024 inpatient surgical site infection rate was 1.21%, a slight increase from 1.19% in 2023; the range from 2020 to 2024 was 1.19% to 1.26%. Out of 437 hospitals, 232 reported zero infections for the entire year, but the standard deviation between institutions once surged to 4.39 percentage points during the pandemic, only dropping to 1.18 in 2024; the maximum value also fell from over 50% to 14.9%. Infections not only prolong hospital stays but may also require additional surgery. This article uses National Health Insurance Administration (NHIA) monitoring indicators to break down the five-year changes of this negative indicator and how the pandemic affected both the numerator and denominator.

閱讀全文